Pregnancy decision-making in women with multiple sclerosis treated with natalizumab
Emilio Portaccio(University of Florence), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla), Angelo Ghezzi, Lucia Moiola(Vita-Salute San Raffaele University), Francesca Rinaldi(San Raffaele University of Rome), Carla Tortorella(Carlo Forlanini Hospital), Vittorio Martinelli(Vita-Salute San Raffaele University), Maria Giovanna Marrosu(University of Cagliari), María Trojano(University of Bari Aldo Moro), Alice Laroni(Azienda Ospedaliera di Padova), Gıancarlo Comı(Casa di Cura Columbus), Antonio Uccelli(Istituti di Ricovero e Cura a Carattere Scientifico), Maria Pia Amato(University of Florence), Roberta Lanzillo(University of Naples Federico II), Damiano Paolicelli(University of Bari Aldo Moro), Luisa Pastò(University of Florence), Laura De Giglio(Vita-Salute San Raffaele University), Paola Cavalla, Vincenzo Morra(University of Naples Federico II), Paolo Gallo(University of Padua), Marta Giannini(Vita-Salute San Raffaele University), Carlo Pozzilli(Sapienza University of Rome), Eleonora Cocco(University of Cagliari), Pietro Annovazzi(Vita-Salute San Raffaele University), Claudio Solaro(Rina Services (Italy))
Cited by 64
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k